SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?

Saborni Chakraborty; Vamsee Mallajosyula; Cristina M. Tato; Gene S. Tan; Taia T. Wang

doi:10.1016/j.addr.2021.01.014

SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?

Saborni Chakraborty, Vamsee Mallajosyula, Cristina M. Tato, Gene S. Tan, Taia T. Wang

Research output: Contribution to journal › Review article › peer-review

70 Scopus citations

Abstract

The ongoing SARS-CoV-2 pandemic has led to the focused application of resources and scientific expertise toward the goal of developing investigational vaccines to prevent COVID-19. The highly collaborative global efforts by private industry, governments and non-governmental organizations have resulted in a number of SARS-CoV-2 vaccine candidates moving to Phase III trials in a period of only months since the start of the pandemic. In this review, we provide an overview of the preclinical and clinical data on SARS-CoV-2 vaccines that are currently in Phase III clinical trials and in few cases authorized for emergency use. We further discuss relevant vaccine platforms and provide a discussion of SARS-CoV-2 antigens that may be targeted to increase the breadth and durability of vaccine responses.

Original language	English
Pages (from-to)	314-338
Number of pages	25
Journal	Advanced Drug Delivery Reviews
Volume	172
DOIs	https://doi.org/10.1016/j.addr.2021.01.014
State	Published - May 2021
Externally published	Yes

Keywords

COVID-19
ORF3a
Phase III vaccine trials
Pre-fusion S protein
SARS-CoV-2 vaccine
Vaccine platform

Access to Document

10.1016/j.addr.2021.01.014

Cite this

@article{c8d6d150be4946ad9095ac91d7c22037,

title = "SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?",

abstract = "The ongoing SARS-CoV-2 pandemic has led to the focused application of resources and scientific expertise toward the goal of developing investigational vaccines to prevent COVID-19. The highly collaborative global efforts by private industry, governments and non-governmental organizations have resulted in a number of SARS-CoV-2 vaccine candidates moving to Phase III trials in a period of only months since the start of the pandemic. In this review, we provide an overview of the preclinical and clinical data on SARS-CoV-2 vaccines that are currently in Phase III clinical trials and in few cases authorized for emergency use. We further discuss relevant vaccine platforms and provide a discussion of SARS-CoV-2 antigens that may be targeted to increase the breadth and durability of vaccine responses.",

keywords = "COVID-19, ORF3a, Phase III vaccine trials, Pre-fusion S protein, SARS-CoV-2 vaccine, Vaccine platform",

author = "Saborni Chakraborty and Vamsee Mallajosyula and Tato, {Cristina M.} and Tan, {Gene S.} and Wang, {Taia T.}",

note = "Publisher Copyright: {\textcopyright} 2021 The Authors",

year = "2021",

month = may,

doi = "10.1016/j.addr.2021.01.014",

language = "English",

volume = "172",

pages = "314--338",

journal = "Advanced Drug Delivery Reviews",

issn = "0169-409X",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - SARS-CoV-2 vaccines in advanced clinical trials

T2 - Where do we stand?

AU - Chakraborty, Saborni

AU - Mallajosyula, Vamsee

AU - Tato, Cristina M.

AU - Tan, Gene S.

AU - Wang, Taia T.

PY - 2021/5

Y1 - 2021/5

N2 - The ongoing SARS-CoV-2 pandemic has led to the focused application of resources and scientific expertise toward the goal of developing investigational vaccines to prevent COVID-19. The highly collaborative global efforts by private industry, governments and non-governmental organizations have resulted in a number of SARS-CoV-2 vaccine candidates moving to Phase III trials in a period of only months since the start of the pandemic. In this review, we provide an overview of the preclinical and clinical data on SARS-CoV-2 vaccines that are currently in Phase III clinical trials and in few cases authorized for emergency use. We further discuss relevant vaccine platforms and provide a discussion of SARS-CoV-2 antigens that may be targeted to increase the breadth and durability of vaccine responses.

AB - The ongoing SARS-CoV-2 pandemic has led to the focused application of resources and scientific expertise toward the goal of developing investigational vaccines to prevent COVID-19. The highly collaborative global efforts by private industry, governments and non-governmental organizations have resulted in a number of SARS-CoV-2 vaccine candidates moving to Phase III trials in a period of only months since the start of the pandemic. In this review, we provide an overview of the preclinical and clinical data on SARS-CoV-2 vaccines that are currently in Phase III clinical trials and in few cases authorized for emergency use. We further discuss relevant vaccine platforms and provide a discussion of SARS-CoV-2 antigens that may be targeted to increase the breadth and durability of vaccine responses.

KW - COVID-19

KW - ORF3a

KW - Phase III vaccine trials

KW - Pre-fusion S protein

KW - SARS-CoV-2 vaccine

KW - Vaccine platform

UR - http://www.scopus.com/inward/record.url?scp=85102421377&partnerID=8YFLogxK

U2 - 10.1016/j.addr.2021.01.014

DO - 10.1016/j.addr.2021.01.014

M3 - Review article

C2 - 33482248

AN - SCOPUS:85102421377

SN - 0169-409X

VL - 172

SP - 314

EP - 338

JO - Advanced Drug Delivery Reviews

JF - Advanced Drug Delivery Reviews

ER -

SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?

Abstract

Keywords

Access to Document

Fingerprint

Cite this